Vivos Q1 revenue up 6% to $3.9M; operating expenses cut 20%; net loss narrows

Vivos Therapeutics, Inc.

Revenue $3.9M (+6% YoY); gross margin 61% vs 70% on higher VIP training costs.
Operating expenses fell 20%; net loss reduced with $3.2M non-cash derivative gain.
VIP enrollments 38 (+19% YoY); VIP revenue $1.3M (+42%). Cash $7.0M.
Acquired AFD patents/TMD-Bruxism products; POD study showed 92% migraine resolution.
Targeting positive cash flow in Q1 2024; multiple DSO/DME pilots underway.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vivos Therapeutics, Inc. reported first quarter ended March 31, 2023 results: revenue $3.9 million.

Period: first quarter ended March 31, 2023
Revenue: $3.9 million
Result: reported results

Exact text from the filing

Revenue was $3.9 million for the first quarter of 2023

View on SEC.gov

Browse all earnings releases →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-020595

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.